American Medical Innovation and Investment Act of 2024 (Sec. 5)

Proposed 2024-06-25 | Official source

Summary

Requires the Secretary of Health and Human Services to issue guidance by January 1, 2026, on Medicare payment requirements for remote monitoring devices with AI components that transmit data to healthcare providers for patient management and treatment.

  • This machine-generated summary is awaiting review by an AGORA editor. Use with caution.

Key facts

🏛️ This document was proposed and/or enacted by the United States Congress but is now defunct. For authoritative text and metadata, visit the official source.

📜 This document's name is American Medical Innovation and Investment Act of 2024 (Sec. 5). It is part of American Medical Innovation and Investment Act of 2024.

↳ This document is part of a longer one: American Medical Innovation and Investment Act of 2024. Some AGORA documents are "split off" from longer documents that mix AI and non-AI content, such as omnibus authorization or appropriations laws in the United States Congress. Read more >>

Themes AI risks, applications, governance strategies, and other themes addressed in AGORA documents.

Thematic tags are in progress.

Full text

  • This is an unofficial copy. The document has been archived and reformatted in plaintext for AGORA. Footnotes, tables, and similar material may be omitted. For the official text, visit the original source.
SEC. 5. GUIDANCE ON MEDICARE PAYMENT FOR CERTAIN ITEMS INVOLVING ARTIFICIAL INTELLIGENCE. Not later than January 1, 2026, the Secretary of Health and Human Services shall use existing communications mechanisms to issue guidance on requirements for payment under part B of title XVIII of the Social Security Act (42 U.S.C. 1395j et seq.) for remote monitoring devices, such as continuous glucose monitors, that— (1) use an artificial intelligence component (such as a continuous adjustment component); and (2) transmit information to a health care provider for purposes of management and treatment of an individual.